Walleye Trading
ADMA icon

Walleye Trading’s ADMA Biologics ADMA Stock Holding History

Walleye Trading’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-30,776
Closed -$110K – 5024
2023
Q3 		$110K Buy
+30,776
New +$118K ﹤0.01% 3924
2016
Q3 		– Sell
-1,300
Closed -$8K – 4765
2016
Q2 		$8K Buy
1,300
+400
+44% +$2.8K ﹤0.01% 4876
2016
Q1 		$7K Buy
+900
New +$5.14K ﹤0.01% 4839

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Walleye Trading's ADMA Position: Q4 2023 in Review

Walleye Trading sold out of ADMA Biologics (ADMA) in Q4 2023, closing a stake of 30,776 shares — an estimated $110K sold.

Walleye Trading first reported a position in ADMA in Q1 2016 and held it in 3 quarters. The position peaked at $110K in Q3 2023. 184 funds tracked by Wall St. Rank hold ADMA as of Q4 2023.

  • Walleye Trading reported no remaining ADMA Biologics position as of Q4 2023 after selling out during the quarter.
  • Walleye Trading sold 30,776 ADMA Biologics shares in Q4 2023, an estimated $110K.
  • Walleye Trading first reported a position in ADMA Biologics in Q1 2016 and held it in 3 quarters.
  • Walleye Trading's ADMA Biologics position peaked at $110K in Q3 2023.
  • 184 funds tracked by Wall St. Rank held ADMA Biologics as of Q4 2023.

Based on Walleye Trading's 13F filing for Q4 2023, filed 14 Feb 2024.